Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Do heel-unloading orthoses improve clinical outcomes in patients after surgical treatment of calcaneal fracture? A propensity-matched, multicenter analysis of the TRON database.
Kagami Y, Tokutake K, Takegami Y, Okui N, Sakai T, Inoue H, Kanemura T, Hanabayashi M, Ito O, Kanayama Y, Maruyama K, Yoshida H, Ando T, Sugimoto R, Sugimoto T, Imagama S. Kagami Y, et al. Among authors: hanabayashi m. Prosthet Orthot Int. 2022 Dec 1;46(6):569-575. doi: 10.1097/PXR.0000000000000168. Epub 2022 Jul 1. Prosthet Orthot Int. 2022. PMID: 36515902
Reasons and risk factors for discontinuation of treatment with any biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: A long-term observational study.
Terabe K, Takahashi N, Asai S, Hirano Y, Kanayama Y, Yabe Y, Oguchi T, Fujibayashi T, Ishikawa H, Hanabayashi M, Hattori Y, Suzuki M, Kishimoto K, Ohashi Y, Imaizumi T, Imagama S, Kojima T. Terabe K, et al. Among authors: hanabayashi m. Mod Rheumatol. 2023 Aug 25;33(5):891-898. doi: 10.1093/mr/roac090. Mod Rheumatol. 2023. PMID: 35975317
Effectiveness of tacrolimus concomitant with biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
Terabe K, Takahashi N, Asai S, Hirano Y, Kanayama Y, Yabe Y, Oguchi T, Fujibayashi T, Ishikawa H, Hanabayashi M, Hattori Y, Suzuki M, Kishimoto K, Ohashi Y, Imaizumi T, Imagama S, Kojima T. Terabe K, et al. Among authors: hanabayashi m. Mod Rheumatol. 2023 Mar 2;33(2):292-301. doi: 10.1093/mr/roac025. Mod Rheumatol. 2023. PMID: 35289372
Comparison of the effects of baricitinib and tocilizumab on disease activity in patients with rheumatoid arthritis: a propensity score matching analysis.
Asai S, Takahashi N, Kobayakawa T, Kaneko A, Watanabe T, Kato T, Nishiume T, Ishikawa H, Yoshioka Y, Kanayama Y, Watanabe T, Hirano Y, Hanabayashi M, Yabe Y, Yokota Y, Suzuki M, Terabe K, Ishiguro N, Imagama S, Kojima T. Asai S, et al. Among authors: hanabayashi m. Clin Rheumatol. 2021 Aug;40(8):3143-3151. doi: 10.1007/s10067-021-05815-3. Epub 2021 Jun 16. Clin Rheumatol. 2021. PMID: 34136969
Higher doses of methotrexate associated with discontinuation of oral glucocorticoids after initiation of biological DMARDs: A retrospective observational study based on data from a Japanese multicenter registry study.
Suzuki M, Kojima T, Takahashi N, Asai S, Terabe K, Kaneko A, Hirano Y, Hanabayashi M, Oguchi T, Takagi H, Kanayama Y, Yabe Y, Funahashi K, Fujibayashi T, Tsuboi S, Ito T, Yoshioka Y, Ishikawa H, Sobue Y, Nishiume T, Yokota Y, Ishiguro N. Suzuki M, et al. Among authors: hanabayashi m. Mod Rheumatol. 2021 Jul;31(4):796-802. doi: 10.1080/14397595.2021.1879428. Epub 2021 Feb 25. Mod Rheumatol. 2021. PMID: 33492191
Predictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: data from a Japanese multicenter registry.
Takahashi N, Asai S, Kobayakawa T, Kaneko A, Watanabe T, Kato T, Nishiume T, Ishikawa H, Yoshioka Y, Kanayama Y, Watanabe T, Hirano Y, Hanabayashi M, Yabe Y, Yokota Y, Suzuki M, Sobue Y, Terabe K, Ishiguro N, Kojima T. Takahashi N, et al. Among authors: hanabayashi m. Sci Rep. 2020 Dec 14;10(1):21907. doi: 10.1038/s41598-020-78925-8. Sci Rep. 2020. PMID: 33318522 Free PMC article. Clinical Trial.
A retrospective analysis of the relationship between anti-cyclic citrullinated peptide antibody and the effectiveness of abatacept in rheumatoid arthritis patients.
Kida D, Takahashi N, Kaneko A, Hirano Y, Fujibayashi T, Kanayama Y, Hanabayashi M, Yabe Y, Takagi H, Oguchi T, Kato T, Funahashi K, Matsumoto T, Ando M, Kuwatsuka Y, Tanaka E, Yasuoka H, Kaneko Y, Hirata S, Murakami K, Sobue Y, Nishiume T, Suzuki M, Yokota Y, Terabe K, Asai S, Ishiguro N, Kojima T. Kida D, et al. Among authors: hanabayashi m. Sci Rep. 2020 Nov 12;10(1):19717. doi: 10.1038/s41598-020-76842-4. Sci Rep. 2020. PMID: 33184461 Free PMC article.
Predictors of disease flare after discontinuation of concomitant methotrexate in Japanese patients with rheumatoid arthritis treated with tocilizumab.
Asai S, Takahashi N, Hayashi M, Hanabayashi M, Kanayama Y, Takemoto T, Yabe Y, Shioura T, Ishikawa H, Yoshioka Y, Kato T, Hirano Y, Fujibayashi T, Hattori Y, Kobayakawa T, Ando M, Kuwatsuka Y, Matsumoto T, Asai N, Sobue Y, Nishiume T, Suzuki M, Ishiguro N, Kojima T. Asai S, et al. Among authors: hanabayashi m. Joint Bone Spine. 2020 Dec;87(6):596-602. doi: 10.1016/j.jbspin.2020.06.001. Epub 2020 Jun 10. Joint Bone Spine. 2020. PMID: 32534200 Free article.
Improvement in matrix metalloproteinase-3 independently predicts low disease activity at 52 weeks in bio-switch rheumatoid arthritis patients treated with abatacept.
Takemoto T, Takahashi N, Kida D, Kaneko A, Hirano Y, Fujibayashi T, Kanayama Y, Hanabayashi M, Yabe Y, Takagi H, Oguchi T, Kato T, Funahashi K, Matsumoto T, Sobue Y, Nishiume T, Suzuki M, Yokota Y, Terabe K, Asai S, Ishiguro N, Kojima T. Takemoto T, et al. Among authors: hanabayashi m. Clin Exp Rheumatol. 2020 Sep-Oct;38(5):933-939. Epub 2020 Feb 4. Clin Exp Rheumatol. 2020. PMID: 32083543 Free article.
27 results